vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and EVERSPIN TECHNOLOGIES INC. (MRAM). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $14.9M, roughly 1.0× EVERSPIN TECHNOLOGIES INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -2.0%, a 3.8% gap on every dollar of revenue. On growth, EVERSPIN TECHNOLOGIES INC. posted the faster year-over-year revenue change (13.2% vs 11.5%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
CSBR vs MRAM — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $14.9M |
| Net Profit | $268.0K | $-296.0K |
| Gross Margin | 51.7% | 52.7% |
| Operating Margin | 1.2% | 29.0% |
| Net Margin | 1.8% | -2.0% |
| Revenue YoY | 11.5% | 13.2% |
| Net Profit YoY | -63.2% | — |
| EPS (diluted) | $0.02 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.9M | ||
| Q4 25 | $15.0M | $14.8M | ||
| Q3 25 | $14.0M | $14.1M | ||
| Q2 25 | $12.4M | $13.2M | ||
| Q1 25 | $17.0M | $13.1M | ||
| Q4 24 | $13.5M | $13.2M | ||
| Q3 24 | $14.1M | $12.1M | ||
| Q2 24 | $14.0M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | $268.0K | $1.2M | ||
| Q3 25 | $-436.0K | $54.0K | ||
| Q2 25 | $-1.8M | $-670.0K | ||
| Q1 25 | $4.5M | $-1.2M | ||
| Q4 24 | $728.0K | $1.2M | ||
| Q3 24 | $1.3M | $2.3M | ||
| Q2 24 | $-109.0K | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 51.7% | 50.8% | ||
| Q3 25 | 42.9% | 51.3% | ||
| Q2 25 | 41.1% | 51.3% | ||
| Q1 25 | 61.2% | 51.4% | ||
| Q4 24 | 44.9% | 51.3% | ||
| Q3 24 | 49.7% | 49.2% | ||
| Q2 24 | 48.2% | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | 1.2% | -7.2% | ||
| Q3 25 | -3.8% | -11.0% | ||
| Q2 25 | -16.2% | -14.9% | ||
| Q1 25 | 26.4% | -14.7% | ||
| Q4 24 | 5.4% | -11.8% | ||
| Q3 24 | 9.5% | -17.5% | ||
| Q2 24 | -1.9% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | 1.8% | 8.1% | ||
| Q3 25 | -3.1% | 0.4% | ||
| Q2 25 | -14.9% | -5.1% | ||
| Q1 25 | 26.4% | -8.9% | ||
| Q4 24 | 5.4% | 9.2% | ||
| Q3 24 | 9.3% | 18.8% | ||
| Q2 24 | -0.8% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | $0.02 | $0.05 | ||
| Q3 25 | $-0.03 | $0.00 | ||
| Q2 25 | $-0.12 | $-0.03 | ||
| Q1 25 | $0.31 | $-0.05 | ||
| Q4 24 | $0.05 | $0.07 | ||
| Q3 24 | $0.09 | $0.10 | ||
| Q2 24 | $-0.01 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $40.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $70.2M |
| Total Assets | $30.2M | $83.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.5M | ||
| Q4 25 | $8.5M | $44.5M | ||
| Q3 25 | $10.3M | $45.3M | ||
| Q2 25 | $9.8M | $45.0M | ||
| Q1 25 | $3.2M | $42.2M | ||
| Q4 24 | $2.8M | $42.1M | ||
| Q3 24 | $2.9M | $39.6M | ||
| Q2 24 | $2.6M | $36.8M |
| Q1 26 | — | $70.2M | ||
| Q4 25 | $4.2M | $68.9M | ||
| Q3 25 | $3.5M | $65.8M | ||
| Q2 25 | $3.8M | $64.1M | ||
| Q1 25 | $5.5M | $63.0M | ||
| Q4 24 | $681.0K | $62.6M | ||
| Q3 24 | $-332.0K | $59.3M | ||
| Q2 24 | $-1.9M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | $30.2M | $84.6M | ||
| Q3 25 | $30.5M | $80.3M | ||
| Q2 25 | $32.3M | $78.9M | ||
| Q1 25 | $30.6M | $80.2M | ||
| Q4 24 | $25.2M | $77.8M | ||
| Q3 24 | $24.9M | $72.6M | ||
| Q2 24 | $26.1M | $64.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $570.0K |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $570.0K | ||
| Q4 25 | $-1.7M | $2.6M | ||
| Q3 25 | $600.0K | $881.0K | ||
| Q2 25 | $6.9M | $5.0M | ||
| Q1 25 | $490.0K | $1.4M | ||
| Q4 24 | $-283.0K | $3.8M | ||
| Q3 24 | $311.0K | $2.8M | ||
| Q2 24 | $-1.8M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-2.0M | $-975.0K | ||
| Q3 25 | $554.0K | $543.0K | ||
| Q2 25 | $6.6M | $3.0M | ||
| Q1 25 | $448.0K | $527.0K | ||
| Q4 24 | $-377.0K | $2.1M | ||
| Q3 24 | — | $2.8M | ||
| Q2 24 | $-1.8M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | -13.1% | -6.6% | ||
| Q3 25 | 4.0% | 3.9% | ||
| Q2 25 | 53.5% | 22.9% | ||
| Q1 25 | 2.6% | 4.0% | ||
| Q4 24 | -2.8% | 15.8% | ||
| Q3 24 | — | 22.9% | ||
| Q2 24 | -13.0% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 24.3% | ||
| Q3 25 | 0.3% | 2.4% | ||
| Q2 25 | 2.0% | 15.1% | ||
| Q1 25 | 0.2% | 6.9% | ||
| Q4 24 | 0.7% | 13.2% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | -6.47× | 2.19× | ||
| Q3 25 | — | 16.31× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | 3.16× | ||
| Q3 24 | 0.24× | 1.25× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
